Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.

Thorac Cancer · 2022 · PMC9108038 · PMID 35394119

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

a nonsignificant trendp = 0.056so close (0.05 < p ≤ 0.1)

32 Another report examined the correlation of BMI with PFS and OS in patients with melanoma using ipilimumab and showed a nonsignificant trend toward longer OS in overweight patients, ( p = 0.056, log‐rank test; HR: 1.81, Cl: 95%: 0.98–3.33).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.